• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNA 特征有助于区分前列腺癌早期和晚期生化失败。

MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer.

机构信息

Department of Laboratory Medicine, Keenan Research Centre in the Li Ka Shing Knowledge Institute St. Michael's Hospital, Toronto, Canada;

出版信息

Clin Chem. 2013 Nov;59(11):1595-603. doi: 10.1373/clinchem.2013.205450. Epub 2013 Aug 19.

DOI:10.1373/clinchem.2013.205450
PMID:23958847
Abstract

PURPOSE

Prostate-specific antigen testing has led to overtreatment of prostate cancer (PCa). Only a small subset of PCa patients will have an aggressive disease that requires intensive therapy, and there is currently no biomarker to predict disease aggressiveness at the time of surgery. MicroRNAs (miRNAs) are reported to be involved in PCa pathogenesis.

METHODS

This study involved 105 participants. For the discovery phase, prostatectomy samples were dichotomized to high-risk (n = 27, biochemical failure <36 months after prostatectomy) and low-risk groups (n = 14, ≥ 36 months without biochemical failure). Expression of 754 mature miRNAs was compared between the 2 groups. Linear regression models were built to accurately predict biochemical failure risk. miRNA mimics were transfected into PCa model cell lines to test effects on proliferation and to deduce responding signaling pathways.

RESULTS

We identified 25 differentially expressed miRNAs between the biochemical failure risk groups. Based on the expression of 2-3 miRNAs, 3 logistic regression models were developed, each with a high positive predictive value. Candidate miRNAs and the best-performing model were also verified on an independent PCa set. miRNA-152, featured in the models, was further investigated by using cell line models and was shown to affect cell proliferation. Predicted interaction between miR-152 and (mRNA)ERBB3 (erythroblastic leukemia viral oncogene homolog 3) was experimentally validated in vitro.

CONCLUSIONS

miRNAs can help to predict biochemical failure risk at the time of prostatectomy.

摘要

目的

前列腺特异性抗原检测导致了前列腺癌(PCa)的过度治疗。只有一小部分 PCa 患者会患有需要强化治疗的侵袭性疾病,目前尚无生物标志物可在手术时预测疾病侵袭性。MicroRNAs(miRNAs)据报道参与了 PCa 的发病机制。

方法

本研究涉及 105 名参与者。在发现阶段,将前列腺切除术样本分为高危组(n=27,前列腺切除术后生化失败<36 个月)和低危组(n=14,生化失败≥36 个月)。比较两组之间 754 个成熟 miRNA 的表达。建立线性回归模型以准确预测生化失败风险。将 miRNA 模拟物转染到 PCa 模型细胞系中,以测试对增殖的影响,并推断出相应的信号通路。

结果

我们在生化失败风险组之间鉴定出 25 个差异表达的 miRNA。基于 2-3 个 miRNA 的表达,建立了 3 个逻辑回归模型,每个模型的阳性预测值都很高。候选 miRNA 和表现最佳的模型也在独立的 PCa 组中得到了验证。模型中特征的 miRNA-152 进一步通过使用细胞系模型进行了研究,结果表明其影响细胞增殖。体外实验验证了 miR-152 和(mRNA)ERBB3(红细胞生成性白血病病毒癌基因同源物 3)之间预测的相互作用。

结论

miRNAs 可帮助预测前列腺切除术时的生化失败风险。

相似文献

1
MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer.miRNA 特征有助于区分前列腺癌早期和晚期生化失败。
Clin Chem. 2013 Nov;59(11):1595-603. doi: 10.1373/clinchem.2013.205450. Epub 2013 Aug 19.
2
Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?基于组织的 microRNAs 作为根治性前列腺切除术后生化复发的预测因子:我们能从过去的研究中学到什么?
Int J Mol Sci. 2017 Sep 21;18(10):2023. doi: 10.3390/ijms18102023.
3
Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.前列腺癌根治术后复发的miRNA表达谱的Meta分析。
PLoS One. 2017 Jun 26;12(6):e0179543. doi: 10.1371/journal.pone.0179543. eCollection 2017.
4
miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.miRNAs 可以预测前列腺癌的生化复发,并参与肿瘤的进展。
Int J Oncol. 2011 Nov;39(5):1183-92. doi: 10.3892/ijo.2011.1128. Epub 2011 Jul 18.
5
Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort.在一项回顾性队列研究中,血清微小RNA水平升高与无高级别前列腺癌相关。
PLoS One. 2015 Apr 14;10(4):e0124245. doi: 10.1371/journal.pone.0124245. eCollection 2015.
6
Detection of miRNAs in urine of prostate cancer patients.前列腺癌患者尿液中微小RNA的检测
Medicina (Kaunas). 2016;52(2):116-24. doi: 10.1016/j.medici.2016.02.007. Epub 2016 Mar 11.
7
Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.根治性前列腺切除术后的生化复发和前列腺癌中的 miR-200a 水平。
Prostate. 2012 Aug 1;72(11):1193-9. doi: 10.1002/pros.22469. Epub 2011 Dec 7.
8
Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.可在前列腺活检中检测癌症的候选诊断性微小RNA。
Prostate. 2018 Feb;78(3):178-185. doi: 10.1002/pros.23427. Epub 2017 Dec 11.
9
A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy.一种基于微小RNA的前列腺切除术后挽救性放射治疗后生化失败的预测模型。
PLoS One. 2015 Mar 11;10(3):e0118745. doi: 10.1371/journal.pone.0118745. eCollection 2015.
10
Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.GEMCaP 作为一种基于 DNA 的生物标志物,用于预测前列腺癌根治术后的复发。
J Urol. 2018 Mar;199(3):719-725. doi: 10.1016/j.juro.2017.09.071. Epub 2017 Sep 20.

引用本文的文献

1
Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph-node invasion.原发性前列腺癌中与淋巴结浸润相关的转录组miRNA和mRNA特征。
Clin Transl Med. 2025 Apr;15(4):e70288. doi: 10.1002/ctm2.70288.
2
The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.miR-152 在尿路上皮肿瘤中的作用:潜在的生物标志物和治疗靶点。
Front Immunol. 2024 Nov 13;15:1464327. doi: 10.3389/fimmu.2024.1464327. eCollection 2024.
3
Long non-coding RNA MEG3 regulates the progress of osteoarthritis by regulating the miR-34a/Klotho axis.
长链非编码RNA MEG3通过调控miR-34a/Klotho轴来调节骨关节炎的进展。
Ann Transl Med. 2022 Apr;10(8):454. doi: 10.21037/atm-22-894.
4
Magnetic-enhanced fluorescence sensing of tumor miRNA by combination of MNPs@PDA with duplex specific nuclease.通过磁性纳米粒子@聚多巴胺与双链特异性核酸酶结合实现肿瘤微小RNA的磁增强荧光传感
RSC Adv. 2021 Jan 13;11(5):2968-2975. doi: 10.1039/d0ra09237a. eCollection 2021 Jan 11.
5
Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis.miR-21 对前列腺癌的预后价值:系统评价和荟萃分析。
Biosci Rep. 2022 Jan 28;42(1). doi: 10.1042/BSR20211972.
6
Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome.验证四miRNA 生物标志物panel MiCaP 预测长期前列腺癌结局。
Sci Rep. 2020 Jul 1;10(1):10704. doi: 10.1038/s41598-020-67320-y.
7
Nutraceutical Boom in Cancer: Inside the Labyrinth of Reactive Oxygen Species.营养保健品在癌症领域的热潮:活性氧物种的迷宫之中。
Int J Mol Sci. 2020 Mar 12;21(6):1936. doi: 10.3390/ijms21061936.
8
A New Era of Prostate Cancer Precision Medicine.前列腺癌精准医学的新时代。
Front Oncol. 2019 Nov 26;9:1263. doi: 10.3389/fonc.2019.01263. eCollection 2019.
9
Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.一种新型 4- miRNA 比值模型(MiCaP)用于预测前列腺癌患者术后结局的训练和验证。
Ann Oncol. 2018 Sep 1;29(9):2003-2009. doi: 10.1093/annonc/mdy243.
10
A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting .一种多平台方法确定 miR-152-3p 作为前列腺癌中常见的受表观遗传调控的肿瘤抑制因子,针对.
Clin Epigenetics. 2018 Mar 27;10:40. doi: 10.1186/s13148-018-0475-2. eCollection 2018.